D-Arginine
CAS RN: 157-06-2
| Solubility in water | Colorless & clear (c=5) |
| Specific rotation [α]D20 | -26.5°～-27.8°(c= 8, 6M-HCl) |
| Loss on drying | Not more than 0.5% |
| Residue on ignition (as sulfate) | Not more than 0.2% |
| Chloride (Cl) | Not more than 0.05% |
| Sulfate (SO4) | Not more than 0.03% |
| Heavy metals (as Pb) | Not more than 10ppm |
| Iron (Fe) | Not more than 10ppm |
| Ammonium (NH4) | Not more than 0.02% |
| Arsenic (As2O3) | Not more than 1ppm |
| Other amino acids | Not detected by T.L.C.(The spotted amount, 20μg) |
| Assay | 98.5%～101.0% |
| L-Isomer | Not more than 0.5% |
We are professional D-Arginine manufacturer and ARGININE,D supplier in China, We offer quality (R)-2-Amino-5-guanidinopentanoic acid you can fully trust, also we have India factory and producer of ARGININE,D,Pls send inquiry of D-Arginine CAS:157-06-2 to info@nbinno.com if you have any interests, thank you!
Related News: Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).3-Ureidopropyltriethoxysilane CAS:116912-64-2 Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.cyclobutanamine CAS:2516-34-9 The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon.2-Fluoro-3-methylaniline Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.
